Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-06-01

Reporting Person: Dunlop A. Sinclair (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-01	Common Stock	J	31855	$0.00	Disposed	0	Indirect
2021-06-01	Common Stock	J	13108	$0.00	Acquired	73108	Direct
2021-06-01	Common Stock	J	2682	$0.00	Acquired	303361	Indirect

Footnotes

F1: Distributions from MASA Life Science Ventures, LP ("MASA"), of which the reporting person is a managing partner. Of the 31,855 shares distributed by MASA, 13,108 were distributed to the reporting person and 2,682 were distributed to Epidarex Capital I, LP ("Epidarex").

F2: The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.

F3: The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.